The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Aims Coronary artery disease (CAD) is a common cause of heart failure (HF). Whether
coronary revascularization improves outcomes in patients with HF receiving guideline …

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more
recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in …

BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is prevalent and
associated with adverse outcomes in heart failure with mildly reduced or preserved ejection …

Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …

Aims Patients recently hospitalized for heart failure (HF) often have unstable
haemodynamics and experience worsening renal failure, and are at elevated risk for …

Sodium–glucose co-transporter 2 (SGLT2) inhibitors improve outcomes in heart failure with
mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Two prospective large …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as an important
approach for the treatment of heart failure in patients with or without diabetes. Although the …

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed as
glucose-lowering agents in patients with type-2 diabetes. However, available data from …

Hypertension remains the leading cause of morbidity and mortality worldwide. Despite its
prevalence, the development of novel antihypertensive therapies has only recently …